Amendments in FDI Policy for India’s Pharma Sectors

November 10, 2011 Posted by India Briefing Reading Time: < 1 minute

Nov. 10 – The government of India has already allowed 100 percent FDI into the pharmaceuticals industry. Recently, the government has reviewed its policy in the particular sector. Below are the specific points:

FDI, up to 100 percent, under the automatic route, would continue to be permitted for greenfield investments in the pharmaceuticals sector.
FDI, up to 100 percent, would be permitted for brown field investments (i.e. investments in existing companies), in the pharmaceuticals sector, under the government approval route.

As a result, the following amendment is made in “Circular 2 of 2011- Consolidated FDJ Policy,” dated September 30, 2011, issued by the Department of Industrial Policy and Promotion:

Insertion of a new paragraph 6.2.25

A new paragraph (6.2.25) is inserted as below:

Please note that below amendments will be effective immediately. The decision will be reviewed after six months by the government.

Dezan Shira & Associates is a boutique professional services firm providing foreign direct investment business advisory, tax, accounting, payroll and due diligence services for multinational clients in India. For more information, please contact info@dezshira.com, visit www.dezshira.com, or download the firm’s brochure here.